Dr. Daniel Lenihan, has been active in clinical research in cardiology, and specifically in heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current projects encompass early phase clinical trials in heart failure, including the ongoing Phase 1B trial of neuregulin in heart failure in conjunction with Acorda, Inc., the Cardiology PI of a multicenter study (in conjunction with MD Anderson Cancer Center) using cardiac biomarkers to detect cardiotoxicity during anthracycline based therapy (PREDICT), and the PI for a multicenter trial examining the cardiovascular effects of proteasome inhibitor therapy for relapsed multiple myeloma (PROTECT). He is also the USA/Canada based president of the International CardiOncology Society-North America, a diverse international group of committed practitioners and researchers whose goal is to enhance clinical practice and patient outcomes while fostering collaboration among cardiology and oncology colleagues throughout the world (www.icosna.org). He is active in the American College of Cardiology (Cardio-Oncology Section Leadership), European Society of Cardiology (Guideline/Position Paper Committee for Cardiotoxicity), and the American Society of Clinical Oncology (Survivorship Guideline Committee Co-chair) as well as several other professional groups whose interests may be involved with cardio-oncology and heart failure. He is currently the PI in over 20 active clinical trials in heart failure, cardio-oncology and amyloidosis. He has been directly involved in many recent highly referenced publications with these topics in mind.